EGFR and posterior cortical atrophy: The SMAD4 gene is frequently mutated in PCa, correlates with changes in altered histopathological transitions, metastatic disease, and poor prognosis and is associated with a higher mortality rate in patients receiving anti-EGFR/Akt/mTOR therapy [15].